In this month’s “Hot Topic,” Anja Roden, M.D., discusses new entities and changes of terminology in the 2021 World Health Organization (WHO) classification of lung tumors as well as the nomenclature in small biopsies.
In this month’s “Hot Topic,” Anja Roden, M.D., will discuss the role of PD-L1 interaction in the immune system, challenges with PD-L1 testing, and current PD-L1 testing in Non-Small Cell Lung Carcinoma (NSCLC).
In this month’s “Hot Topic,” Anja Roden, M.D., discusses mesothelial proliferations, their challenges, and which ancillary testing might help to overcome some of those challenges.
Kevin Halling, M.D., gives an overview of the lung cancer NGS panel available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.
Oncology testing is rapidly advancing—from new technology and discoveries in molecular biomarkers to emerging therapies. Mayo Clinic Laboratories innovates at the speed of medical advancement, and offers comprehensive options for diagnostic, prognostic, and predictive lung cancer testing.